Abstract-The risk of developing pregnancy-induced hypertension and preeclampsia is higher in obese pregnant women.
H ypertension is clearly associated with obesity, 1 predisposing obese individuals to adverse cardiovascular outcomes. In obesity, the gut microbiome is altered, a phenomenon known as dysbiosis, which could contribute to hypertension and its complications, potentially by increasing low-grade inflammation. 2 Gut microbiome dysbiosis is also associated with cardiovascular disease. 3 In a rat model of spontaneous hypertension, the gut microbiome is less diverse, is less rich, and shows a higher Firmicutes:Bacteroidetes ratio.
2 A higher Firmicutes:Bacteroidetes ratio has also been reported for obese humans 4 and in people with systolic hypertension. 2 Obese school girls have higher blood pressure and a lower abundance of Bacteroidetes in their gut microbiota than normal-weight girls. 5 The gut microbiota can potentially influence host blood pressure through multiple mechanisms. Bacteria belonging to the Streptococcus, Escherichia, Lactobacillus, and Bifidobacterium genera can synthesize neurotransmitters within the autonomic nervous system. 6 Alterations in the prevalence of these bacteria may alter vascular tone and contribute to the development of hypertension. 7 The gut microbiota influences host inflammatory response, 8 altering endothelial function, which can impact on host blood pressure. Short-chain fatty acid (SCFA) production by the gut microbiota is associated with hypertension, 9 as a result of the influence of SCFA on vascular tone.
The gut microbiota of hypertensive rats has lower abundance of Bifidobacteria and fewer SCFA-producing bacteria. 2 Treatment with the antibiotic minocycline increased the numbers of SCFA-producing bacteria while reducing mean arterial blood pressure. 2 Supplementation with probiotics reportedly reduces blood pressure, indicating the importance of the gut microbiota in the regulation of blood pressure outside pregnancy.
Gomez-Arango et al Blood Pressure and Gut Microbiome Butyrate Production 975
The SCFA butyrate is produced from dietary fiber by bacteria in the gastrointestinal lumen. There are 2 main enzymes catalyzing butyrate production: butyrate kinase (Buk) and butyryl-CoA:acetate CoA-transferase (But), which are often used as biomarkers for the detection of butyrate-producing bacteria. 11 Buk catalyzes the formation of butyrate from butyryl-CoA, releasing ATP in the process. 12, 13 But catalyzes the reaction of butyryl-CoA with exogenous acetate to form butyrate and acetyl-CoA. 13, 14 Some butyrate-producing bacteria only express But or Buk, whereas others express both. 12 The main butyrate producers in the human gut belong to the Firmicutes phylum (Coprococci, Eubacterium, Roseburia, and Faecalibacterium genera), 14 but members of other phyla, especially Bacteroidetes (Odoribacter and Alistipes genera), often contribute to the overall butyrogenic pool. SCFAproducing bacteria may affect blood pressure by direct effects of SCFA on vasodilation or through plasminogen activator inhibitor-1 (PAI-1). n-Butyrate increases PAI-1 mRNA in cultured hepatocytes, 15 and SCFA enemas stimulate rectal microcirculation and PAI-1 after aortic graft surgery. 16 It is unclear whether there is a relationship between butyrate production and hypertension in pregnancy.
In obesity, adipocytes from visceral fat secrete inflammatory markers and angiotensinogen. Angiotensinogen activates the renin-angiotensin-aldosterone system, 1 which may result in hypertension. 1 Hypertension causes an injury to the vascular endothelium, eliciting an inflammatory response causing a rise in C-reactive protein, which can induce PAI-1.
17
Circulating PAI-1 is increased in established hypertension and in normotensive children of hypertensive parents. 17 PAI-1 is expressed in adipose tissue, and its levels are increased in obesity. 18 In pregnancies affected by hypertension, including preeclampsia and HELLP syndrome (hemolysis elevated liver enzymes and low platelet), placental PAI-1 expression 19 and circulating PAI-1 levels [20] [21] [22] [23] [24] are increased.
Aim
In this study, the relationships between obesity, the gut microbiome, blood pressure, and PAI-1 levels in overweight and obese pregnant women are examined at 16 weeks gestation.
Materials and Methods

Study Population and Sample Collection
For this study, samples obtained from 205 participants of the SPRING study (the Study of Probiotics in Gestational Diabetes) were obtained. The SPRING study is a registered randomized controlled trial aiming to prevent gestational diabetes mellitus by probiotics supplementation in overweight and obese pregnant women (ANZCTR 12611001208998). 25 At baseline (<16 weeks gestation), detailed demographic and medical history data and a fasting serum sample were collected before randomization. Participants self-collected a fecal sample, which was refrigerated until storage at −80 °C within 24 hours of collection. Pregnancy-induced hypertension encompassing gestational hypertension, preeclampsia, and HELLP syndrome, 26 developing during pregnancy was noted.
Fecal DNA Extraction
0.25 g of stool sample was thawed at 4 °C overnight. For DNA extraction, the RBB+C (repeated bead beating and column) protocol was followed 27 with mechanical sample lysis performed for 3 minutes with a mix of 0.1 and 0.5 mm sterile zirconia beads in the TissueLyser II (Qiagen). The Qiagen AllPrep DNA extraction kit was used to isolate fecal DNA. DNA quantity and quality was analyzed with a Nanodrop ND 1000 spectrophotometer.
Gut Microbiome Sequencing
The V6-V8 regions of the bacterial 16S rRNA gene were amplified from the isolated DNA using the 926F and 1392R primer pair. The sequence for 926F is (5′ -TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGAAACTYAAAKGAATTGRCGG -3′) and for 1392R is (5′ -GTCTCGTGGGCTCGGAGATGTGTATAAGAGACA GACGGGCGGTGWGTRC -3′). This primer pair yields a product of 500 bps, which was cleaned with AMPure XP beads. DNA isolated from Escherichia coli Jm109 was used as positive control and sterile water as the negative control. The Nextera XT Index kit was used to add barcodes, synthesize, quantify, normalize, and pool libraries following the manufacturer's recommendations (Illumina). An Illumina MiSeq system was used for sequencing at the Australian Center for Ecogenomics in Brisbane, Australia. Sequencing data were assembled, demultiplexed, and quality filtered using the QIIME software (Quantitative Insights Into Microbial Ecology v 1.9.1; http://www.qiime.org). 28 Sequences were assigned to operational taxonomic units with a pairwise identity threshold of 97%, and taxonomic classification was determined using the Greengenes reference database. After excluding operational taxonomic units with an overall abundance of <0.0001, a median of 25 400 reads per sample were obtained. Data were rarefied to 3000 sequences per sample to standardize sequence reads across samples. Operational taxonomic unit abundance was analyzed on taxonomic level including Phylum, Class, Order, Family, and Genus.
Butyrate Production Capacity
The 2 main genes for bacterial butyrate production are But and Buk. But encodes butyryl-CoA:acetate-CoA transferase and Buk encodes butyrate kinase. Degenerate real-time polymerase chain reaction was performed to assess expression of But and Buk in each fecal DNA sample. The primer sequences for these assays were Buk (forward: 5′ -TGCTGTWGTTGGWAGAGGYGGA -3′ and reverse: 5′ GCAACIGCYTTTTGATTTAATGCATGG) and But (forward: 5′ GCIGAICATTTCACITGGAAYWSITGGCAYATG 3′ and reverse: 5′ CCTGCCTTTGCAATRTCIACRAANGC 3′). Gene amplification and detection was performed in 96-well plates with SYBR Green polymerase chain reaction 2X master mix (Bio-Rad Laboratories). Each reaction of 15 ng DNA was run in duplicate with a final volume of 20 μL and sterile deionized water as nontemplate control. The amplification cycle used for Buk was 1 cycle of 95 °C for 2 minutes and 40 cycles of 95 °C, 54 °C, 72 °C for 45 seconds, and for But was 1 cycle of 95 °C for 3 minutes and 40 cycles of 94 °C, 53 °C, 72 °C for 30 seconds using the iQ5 real-time polymerase chain reaction machine (Bio-Rad Laboratories, Hercules, CA). Clostridium difficile and Faecalibacterium prausnitzii A2-165 were used to generate standard curves for Buk and But, respectively. Levels of Buk and But gene expression were normalized to the level of total bacteria content assessed using total bacterial gene primer sets (forward: 5′ GCAGGCCTAACACATGCAAGTC 3′ and reverse: 5′ CTGCTGCCTCCCGTAGGAGT 3′). Relative gene expression was calculated using the ΔΔCt method. Overall butyrate production was calculated by determining the centroid values for the expression of Buk and But separately and adding these to provide an indication of the total butyrate-producing gene load for each woman. From each subject, dietary fiber intake was obtained from food frequency records, was stratified into tertiles, and correlated to Buk and But expression.
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recommendations before analysis with the BioPlex 200 using the BioPlex Manager 6.1 software (Bio-Rad).
Statistical Analysis
The data were not normally distributed and are therefore presented as median with interquartile range in all instances. Comparisons between groups were performed with the nonparametric Mann-Whitney U test. The proportions of women developing pregnancy-induced hypertension were compared with a Fisher exact test. Correlation analyses were performed with Spearman rank correlation coefficient tests for gene expression and hormone analyses using GraphPad Prism v6, with a P value <0.05 considered to be statistically significant. For associations between clinical characteristics and gut microbial taxa abundance, bootstrapped Spearman rank correlation coefficient tests were performed using 1000 permutations. Correction for multiple testing was performed using false discovery rate with the Benjamini-Hochberg procedure within the QIIME software. False discovery rate values <0.05 were considered statistically significant.
Results
The characteristics of the cohort at 16 weeks gestation are described in Table 1 . Body mass index (BMI) is positively correlated with both systolic and diastolic blood pressure (Table 2) . When comparing overweight to obese women, obese women have slightly but significantly higher systolic and diastolic blood pressures ( Figure 1A ). The rate of pregnancy-induced hypertension trended to be twice as high in obese women (Table 1) . When analyzing the associations between blood pressure and the proportions of Firmicutes and Bacteroidetes or the Firmicutes:Bacteroidetes ratio, no differences were observed (Table 1) . However, systolic and diastolic blood pressures were negatively correlated to specific families and genera in the gut microbiota including the Odoribacteraceae and Clostridiaceae families (Table 3 ). In addition, the Christensenellaceae family and the Blautia genus were also negatively associated with systolic blood pressure. The abundance of the genus Odoribacter was negatively correlated with systolic blood pressure ( Figure 1B ). To exclude that this effect was driven by BMI, associations between gut microbiota composition and systolic blood pressure were analyzed in overweight and obese women, respectively. The same families and genera were correlated with systolic blood pressure in overweight and obese women when analyzed separately (Table S1 in the online-only Data Supplement; Figure  1C and 1D). However, the correlation coefficients were stronger in overweight women than in obese women. Furthermore, abundance of Odoribacter in the gut microbiota of overweight and obese pregnant women was not independently correlated with BMI (Table S2) .
Because the Odoribacteraceae and Clostridiaceae families are known butyrate producers, we investigated butyrate production capacity by assessing gene expression of 2 known Figure 2B ) and nominally negatively correlated with But expression (ρ=−0.13; P=0.06). Buk but not But expression was negatively correlated with both systolic and diastolic blood pressure ( Figure 2C and Table 2 ). Buk and But expression are not correlated with the abundance of Firmicutes or Bacteroidetes nor with the F:B ratio (data not shown). Because dietary fiber intake may affect butyrate production by increasing the availability of substrate, the relationship between fiber intake and expression of Buk and But was investigated, but no correlation was found. Because decreased butyrate production was associated with higher blood pressure, which itself is linked to circulating PAI-1 levels, we investigated PAI-1 in a subset of 28 overweight and 42 obese women. Obese women had significantly higher circulating PAI-1 levels than overweight women ( Figure 2D and Table 1 ). Furthermore, there was a positive correlation between BMI and PAI-1 levels ( Table 2) . PAI-1 levels were also positively correlated to systolic and diastolic blood pressure (Table 2) . Although there was no correlation between PAI-1 levels and But expression, there was a negative correlation with Buk expression ( Figure 2E and Table 2 ). PAI-1 levels were also negatively correlated with abundance of the butyrate-producing family Odoribactereae, the genus of Odoribacter ( Figure 2F and Table 2 ), and the family Rikenellaceae ( Table 2 ).
Discussion
This study shows that systolic blood pressure is negatively correlated with the abundance of the butyrate producers Odoribacter and Clostridiaceae and expression of the Buk gene in the gut microbiota in overweight and obese pregnant women at 16 weeks gestation. Odoribacter abundance and Buk expression are negatively correlated with the inflammatory marker PAI-1, which itself is positively correlated with blood pressure (Figure 3) .
The results of this study suggest that the expression of the Buk gene by Odoribacteraceae and Clostridiaceae in the gut microbiota in pregnant women at 16 weeks gestation is associated with decreased blood pressure. This relationship is independent of BMI because the correlation between Odoribacter abundance and blood pressure is observed in overweight and obese women separately with stronger correlation coefficients in overweight pregnant women. This suggests that BMI may actually attenuate the effect of Odoribacter abundance on blood pressure especially because BMI itself is not correlated with Odoribacter abundance. This study cannot demonstrate causality, but there are potential mechanisms by which butyrate-producing bacteria could exert influence on host blood pressure. These include via SCFA production and more tentatively through influencing inflammation and PAI-1.
SCFAs can dilate isolated resistance arteries from the human colon in vitro. 29 SCFAs reduce systemic blood pressure via activation of GPR41. 30 The butyrate kinase gene (Buk) is selectively expressed among human butyrate-producing bacteria belonging to Clostridial clusters XI and I. 12 The butyryl-CoA:acetate CoA-transferase (But) is expressed by bacteria belonging mainly to Clostridial clusters XVIa and IV. 12 It is unclear which butyrate-producing pathway is mostly used in the gut microbiota; however, one study suggested that butyrate kinase is the pathway used in most intestinal ecosystems. 12 Members of the Odoribacteraceae, Clostridiaceae, and Rikenellaceae families primarily express the Buk gene. 12 Oral supplementation with butyrate lowers the concentrations of interleukin-1β and tumor necrosis factor-α in response to high-fat diet in mice. 31 Lower production capacity of butyrate may therefore contribute to 
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higher blood pressure in obese pregnant women. The use of sodium butyrate during pregnancy in a rat model increased the expression of antioxidant and nutrient-related genes. 32 In pigs, sodium butyrate supplementation improved embryo development in vitro and enhanced gene expression involved in early development. 33, 34 Lastly, a recent study in rats suggested that hypertension was associated with reductions in the proportions of butyrate-producing bacteria but increases in bacteria that produce lactate. 35 Here, Odoribacter abundance is inversely correlated with both blood pressure and PAI-1. Odoribacter is an anaerobic nonmotile Gram-negative rod, which makes succinate, propionate, acetate, butyrate, isobutyrate, and isovalerate by fermenting carbohydrates in vitro. 36, 37 In the human gastrointestinal tract, there are only 3 species belonging to this genus, with Odoribacter splanchnicus being the prominent one. 37 Fecal butyrate and 3-phenylpropionate concentrations correlate positively with O. splanchnicus abundance in humans. 38 Moreover, lower Odoribacter abundance has been detected in subjects with Crohn's disease, 39 which is characterized by low butyrate-producing capacity. The associations between Odoribacter and blood pressure (data presented here) and metabolism 38 indicate that this species could be a candidate to use as a probiotic. 
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Low-grade inflammation, such as in obesity, can be the result of reduced microbial diversity. The gut microbiome may reduce the synthesis of inflammatory markers by metabolizing the plant polyphenols into urolithins, which can reduce PAI-1 secretion from enterocytes and aortic endothelial cells. 40, 41 In our study, PAI-1 levels were higher in obese women. PAI-1 levels are increased in diabetes, 42 and its gene expression levels are positively correlated with BMI. 43 In men with mild hypertension, BMI and PAI-1 activity are positively correlated, and PAI-1 levels decrease with weight loss. 43 Furthermore, pharmacological treatment of newly diagnosed hypertension reduces PAI-1 levels. 44, 45 In early pregnancy, increased PAI-1 levels are associated with higher risk of later hypertensive disorders in pregnancy. 46 PAI-1 levels are also increased in severe preeclampsia, 23 and polymorphisms in the PAI-1 gene (SERPINE2) have been associated with increased risk of preeclampsia in a meta-analysis. 47 It is not clear whether PAI-1 regulates blood pressure or vice versa; however, one study suggests that inhibition of PAI-1 can reduce hypertension caused by inhibition of nitric oxide synthase. 48 Therefore, manipulation of gut microbiome metabolites reducing PAI-1 levels may lower blood pressure both in pregnancy and outside pregnancy.
In this study, blood pressure is inversely correlated with the abundance of other bacteria from the order of Clostridiales, including the Christensellaceae, Blautia, and Clostrididiaceae families; the last 2 families are known to be important butyrate producers. In addition, members of the Bacteroidales order, Rikenellaceae and Bacteroides, which can harbor butyrate-producing members, were also negatively correlated with blood pressure. A negative correlation between Bacteroides and blood pressure, body weight, and fat mass has been reported. 49, 50 Therefore, supplementation with bacteria belonging to this genus may improve multiple clinical parameters.
The gut microbiota can regulate ≈10% of the host's transcriptome, particularly genes involved in immune response, proliferation, and metabolism. 51 Preeclampsia incidence can be reduced by consumption of probiotics in dairy products. 52 It has been hypothesized that probiotics reduce blood pressure by fermenting food to release bioactive peptides including angiontensin-converting enzyme inhibitory peptides 53 and reduce the production of proinflammatory cytokines. Randomized controlled clinical trials of adequate size should be performed to definitively establish the effects of probiotics on lowering blood pressure.
Perspectives
This study shows that the abundance of butyrate-producing bacteria in the gut microbiome and the number of copies of the butyrate-producing Buk enzyme are inversely correlated to systolic and diastolic blood pressure and the inflammatory marker PAI-1 in overweight and obese women at 16 weeks gestation. Whether this relationship is true for normal-weight pregnant women remains to be investigated. Future studies aimed at manipulation of the gut microbiome by probiotics, prebiotics, or dietary intervention may shed light on whether this is a novel way to aid pregnant women in maintaining healthy blood pressure and reducing low-grade inflammation thereby improving outcomes for mother and baby.
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• This study shows that the abundance of Odoribacter and the expression of the butyrate-producing gene butyrate kinase in the gut microbiome of overweight and obese pregnant women in early second trimester are negatively correlated with PAI-1 concentrations in the circulation and with systolic and diastolic blood pressure.
What Is Relevant?
• The relationship between the composition of the gut microbiome and blood pressure in pregnancy suggests that manipulation of the gut microbiome by altered dietary intake, probiotics, and prebiotics may support the maintenance of normal blood pressure in pregnancy.
Summary
It is not clear whether the composition of the gut microbiome in early pregnancy is related to blood pressure in overweight and obese pregnant women. In this study, this relationship was explored. The results show that there is a relationship between the composition of the gut microbiome and blood pressure. Higher abundance of the butyrate-producing Odoribacter genus is associated with lower systolic and diastolic blood pressure. Higher expression of the butyrate kinase in the gut microbiome is associated with lower blood pressure. Higher Odoribacter abundance and butyrate expression are associated with lower serum plasminogen activator inhibitor-1 concentrations. 
